Document/ExhibitDescriptionPagesSize 1: 8-K Current Report -- form8k HTML 21K
2: EX-99.1 CHARTER Articles of Incorporation/Organization -- HTML 37K
exhibit99-1
6: R1 Cover HTML 40K
8: XML IDEA XML File -- Filing Summary XML 11K
11: XML XBRL Instance -- form8k_htm XML 15K
7: EXCEL IDEA Workbook of Financial Report Info XLSX 8K
4: EX-101.LAB XBRL Labels -- nika-20240301_lab XML 96K
5: EX-101.PRE XBRL Presentations -- nika-20240301_pre XML 64K
3: EX-101.SCH XBRL Schema -- nika-20240301 XSD 12K
9: JSON XBRL Instance as JSON Data -- MetaLinks 25± 35K
10: ZIP XBRL Zipped Folder -- 0001826466-24-000020-xbrl Zip 19K
(State or other jurisdiction of Nika Pharmaceuticals, Inc.)
(Commission File Number)
(IRS Employer Identification No.)
i2269 Merrimack Valley Avenue
iHenderson, iNVi89044 (Address of principal executive offices) (Zip code)
(i702)-i326-3615 Registrant's telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
i|X| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i|_|Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Section 2–Financial Information
Item 2.01 Completion of Acquisition or Disposition of Assets.
Nika Pharmaceuticals, Inc. has gone through a market extension merger with Nika BioTechnology, Inc., effective as of March 1, 2024. The Agreement and Plan of Mergerwas approved by the shareholders and board of directors of both companies on February 12, 2024.
Pursuant to the terms of the merger, Nika BioTechnology, Inc. will merge into Nika Pharmaceuticals, Inc. for which the shareholders of Nika BioTechnology, Inc. will receive, as consideration, one (1) share of NKPH common stock for each share of NIKA common stock that they own.
Both entities have the same board of directors and officers who will continue to remain in the same roles in the consolidated entity. Dimitar Slavchev Savov owns approximately 69% of the common stock and 100% of the Preferred A stock of Nika BioTechnology, Inc, as well as approximately 37% of the common stock and 100% of the Preferred A stock of Nika Pharmaceuticals, Inc.
Pursuant to the terms of the Agreement and Plan of Merger and the approval of the company’s board of directors and shareholders, Nika Pharmaceuticals, Inc. has filed an Amendment to the Articles of Incorporation to increase the number of authorized Preferred A stock from 10,000,000 to 15,000,000, effective as of March 4, 2024 when the amendment was filed with the Colorado Secretary of State.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, hereunto duly authorized.
